1. Home
  2. JFIN vs MLYS Comparison

JFIN vs MLYS Comparison

Compare JFIN & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFIN
  • MLYS
  • Stock Information
  • Founded
  • JFIN 2011
  • MLYS 2019
  • Country
  • JFIN China
  • MLYS United States
  • Employees
  • JFIN N/A
  • MLYS N/A
  • Industry
  • JFIN Finance: Consumer Services
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • JFIN Finance
  • MLYS Health Care
  • Exchange
  • JFIN Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • JFIN 969.7M
  • MLYS 1.0B
  • IPO Year
  • JFIN 2019
  • MLYS 2023
  • Fundamental
  • Price
  • JFIN $14.86
  • MLYS $14.32
  • Analyst Decision
  • JFIN
  • MLYS Strong Buy
  • Analyst Count
  • JFIN 0
  • MLYS 4
  • Target Price
  • JFIN N/A
  • MLYS $27.00
  • AVG Volume (30 Days)
  • JFIN 106.5K
  • MLYS 764.6K
  • Earning Date
  • JFIN 08-26-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • JFIN 5.38%
  • MLYS N/A
  • EPS Growth
  • JFIN 2.88
  • MLYS N/A
  • EPS
  • JFIN 3.43
  • MLYS N/A
  • Revenue
  • JFIN $840,800,386.00
  • MLYS N/A
  • Revenue This Year
  • JFIN N/A
  • MLYS N/A
  • Revenue Next Year
  • JFIN N/A
  • MLYS N/A
  • P/E Ratio
  • JFIN $4.34
  • MLYS N/A
  • Revenue Growth
  • JFIN 4.83
  • MLYS N/A
  • 52 Week Low
  • JFIN $4.00
  • MLYS $8.24
  • 52 Week High
  • JFIN $19.23
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • JFIN 36.37
  • MLYS 50.99
  • Support Level
  • JFIN $15.73
  • MLYS $13.13
  • Resistance Level
  • JFIN $16.85
  • MLYS $14.55
  • Average True Range (ATR)
  • JFIN 0.87
  • MLYS 0.70
  • MACD
  • JFIN -0.36
  • MLYS 0.01
  • Stochastic Oscillator
  • JFIN 31.91
  • MLYS 56.40

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: